Drug Profile
NB 1008
Alternative Names: Fluzone + 60%W805EC; Influenza mucosal vaccine - BlueWillow Biologics; Intranasal nanoemulsion vaccine for influenza - BlueWillow Biologics; Intranasal seasonal influenza vaccine - BlueWillow Biologics; NanoStat™ muscosal influenza vaccine; NB-1008; Transmucosal influenza vaccine - BlueWillow BiologicsLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Influenza virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, In volunteers) in USA (Intranasal, Drops)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, In volunteers) in USA (Intranasal, Spray)
- 09 Mar 2020 NB 1008 is still in phase-I development in Influenza-virus-infections(Prevention, In volunteers) in USA (Intranasal, Drops) (BlueWillow Biologics pipeline March 2020)